Male Hypogonadism Market By Drug Delivery (Topical Gels, Injectables, Transdermal Patches, Others), By Therapy (Testosterone Replacement Therapy, Gonadotropin and Gonadotropin Releasing Hormone Therapy), By Type (Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030.
Hypogonadism is characterized as lack of testosterone level or lack of spermatozoa production, or both. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). Both can be inherited or acquired, due to ageing, hormonal disorders or medicines. In addition, various congenital enzyme abnormalities result in various degrees of androgen resistance in target organs. Hormone levels corroborate the diagnosis. The treatment for gonadotropin-releasing hormone, gonadotropin, or testosterone replacement differs depending on the aetiology.
The factors that drive the global male hypogonadism market are increase in cases of hypogonadism, surge in awareness of hypogonadism, and rise in number of treatment options. In addition, hypogonadism is prevalent in the geriatric population as well as in patients with diabetes and obesity. As a result, increase in population and rise in the incidence and prevalence of chronic disorders, such as diabetes and obesity drive the growth of the market. According to clinical research, testosterone levels in males aged 60–80 years are 20 percent and 80 percent lower, respectively, than testosterone levels in young men. Hypogonadism is most common in men aged above 60. In countries like Japan, China, and the U.S. there is surge in demand for male hypogonadism treatments, owing to increase in geriatric population and surge in infertility rates.
The male hypogonadism market is segmented on the basis of therapy, drug delivery, type, and region. Depending on therapy, it is divided into testosterone replacement therapy and gonadotropin & gonadotropin-releasing hormones therapy. The gonadotropin-releasing hormones therapy segment is segmented into luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (HCG), and gonadotropin-releasing hormone (GNRH). According to drug delivery, it is fragmented into topical gels, injectable, transdermal patches, and others. As per the type, it is classified into Klinefelter’s syndrome, Kallmann syndrome, pituitary disorders, and others. Region wise, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.
Major key players operating in the global male hypogonadism market are Allergan PLC., Bayer AG, Eli Lily & Company, Endo Iternational PLC., Ferring Holdings SA, Finox Biotech, Merck & Co. Inc., Pfizer, Perrigo Company PLC., Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the male hypogonadism market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global male hypogonadism market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Klinefelters Syndrome
Kallmann Syndrome
Pituitary Disorders
Others
By Drug Delivery
Topical Gels
Injectables
Transdermal Patches
Others
By Therapy
Testosterone Replacement Therapy
Gonadotropin and Gonadotropin Releasing Hormone Therapy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Rest of Europe
Asia-Pacific
India
Rest of Asia-Pacific
Japan
China
LAMEA
Latin America
Middle East
Africa
Key Market Players
Allergan plc
Pfizer Inc.
Bayer AG
Eli Lilly and Company Ltd.
Endo International plc.
Merck & Co., Inc.
Ferring
Finox Biotec
Teva Pharmaceutical Industries Ltd.
Perrigo Company plc
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: MALE HYPOGONADISM MARKET, BY DRUG DELIVERY
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Topical Gels
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Injectables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Transdermal Patches
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: MALE HYPOGONADISM MARKET, BY THERAPY
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Testosterone Replacement Therapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Gonadotropin and Gonadotropin Releasing Hormone Therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: MALE HYPOGONADISM MARKET, BY TYPE
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Klinefelters Syndrome
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Kallmann Syndrome
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Pituitary Disorders
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- CHAPTER 7: MALE HYPOGONADISM MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Delivery
- 7.2.3 North America Market size and forecast, by Therapy
- 7.2.4 North America Market size and forecast, by Type
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Delivery
- 7.2.5.1.2 Market size and forecast, by Therapy
- 7.2.5.1.3 Market size and forecast, by Type
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Delivery
- 7.2.5.2.2 Market size and forecast, by Therapy
- 7.2.5.2.3 Market size and forecast, by Type
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Delivery
- 7.2.5.3.2 Market size and forecast, by Therapy
- 7.2.5.3.3 Market size and forecast, by Type
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Delivery
- 7.3.3 Europe Market size and forecast, by Therapy
- 7.3.4 Europe Market size and forecast, by Type
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Delivery
- 7.3.5.1.2 Market size and forecast, by Therapy
- 7.3.5.1.3 Market size and forecast, by Type
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Delivery
- 7.3.5.2.2 Market size and forecast, by Therapy
- 7.3.5.2.3 Market size and forecast, by Type
- 7.3.5.3 U.K.
- 7.3.5.3.1 Market size and forecast, by Drug Delivery
- 7.3.5.3.2 Market size and forecast, by Therapy
- 7.3.5.3.3 Market size and forecast, by Type
- 7.3.5.4 Rest of Europe
- 7.3.5.4.1 Market size and forecast, by Drug Delivery
- 7.3.5.4.2 Market size and forecast, by Therapy
- 7.3.5.4.3 Market size and forecast, by Type
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Delivery
- 7.4.3 Asia-Pacific Market size and forecast, by Therapy
- 7.4.4 Asia-Pacific Market size and forecast, by Type
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Delivery
- 7.4.5.1.2 Market size and forecast, by Therapy
- 7.4.5.1.3 Market size and forecast, by Type
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Delivery
- 7.4.5.2.2 Market size and forecast, by Therapy
- 7.4.5.2.3 Market size and forecast, by Type
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Drug Delivery
- 7.4.5.3.2 Market size and forecast, by Therapy
- 7.4.5.3.3 Market size and forecast, by Type
- 7.4.5.4 Rest of Asia-Pacific
- 7.4.5.4.1 Market size and forecast, by Drug Delivery
- 7.4.5.4.2 Market size and forecast, by Therapy
- 7.4.5.4.3 Market size and forecast, by Type
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Delivery
- 7.5.3 LAMEA Market size and forecast, by Therapy
- 7.5.4 LAMEA Market size and forecast, by Type
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Latin America
- 7.5.5.1.1 Market size and forecast, by Drug Delivery
- 7.5.5.1.2 Market size and forecast, by Therapy
- 7.5.5.1.3 Market size and forecast, by Type
- 7.5.5.2 Middle East
- 7.5.5.2.1 Market size and forecast, by Drug Delivery
- 7.5.5.2.2 Market size and forecast, by Therapy
- 7.5.5.2.3 Market size and forecast, by Type
- 7.5.5.3 Africa
- 7.5.5.3.1 Market size and forecast, by Drug Delivery
- 7.5.5.3.2 Market size and forecast, by Therapy
- 7.5.5.3.3 Market size and forecast, by Type
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Allergan plc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Pfizer Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Bayer AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Eli Lilly and Company Ltd.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Endo International plc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Merck & Co., Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Ferring
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Finox Biotec
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Teva Pharmaceutical Industries Ltd.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Perrigo Company plc
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
- TABLE 2. MALE HYPOGONADISM MARKET REVENUE, FOR TOPICAL GELS, BY REGION , 2020-2030,($MILLION)
- TABLE 3. MALE HYPOGONADISM MARKET TOPICAL GELS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. MALE HYPOGONADISM MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
- TABLE 5. MALE HYPOGONADISM MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. MALE HYPOGONADISM MARKET REVENUE, FOR TRANSDERMAL PATCHES, BY REGION , 2020-2030,($MILLION)
- TABLE 7. MALE HYPOGONADISM MARKET TRANSDERMAL PATCHES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 8. MALE HYPOGONADISM MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 9. MALE HYPOGONADISM MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 10. GLOBAL MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 11. MALE HYPOGONADISM MARKET REVENUE, FOR TESTOSTERONE REPLACEMENT THERAPY, BY REGION , 2020-2030,($MILLION)
- TABLE 12. MALE HYPOGONADISM MARKET TESTOSTERONE REPLACEMENT THERAPY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. MALE HYPOGONADISM MARKET REVENUE, FOR GONADOTROPIN AND GONADOTROPIN RELEASING HORMONE THERAPY, BY REGION , 2020-2030,($MILLION)
- TABLE 14. MALE HYPOGONADISM MARKET GONADOTROPIN AND GONADOTROPIN RELEASING HORMONE THERAPY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 15. GLOBAL MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 16. MALE HYPOGONADISM MARKET REVENUE, FOR KLINEFELTERS SYNDROME, BY REGION , 2020-2030,($MILLION)
- TABLE 17. MALE HYPOGONADISM MARKET KLINEFELTERS SYNDROME BY COUNTRY, 2020-2030,($MILLION)
- TABLE 18. MALE HYPOGONADISM MARKET REVENUE, FOR KALLMANN SYNDROME, BY REGION , 2020-2030,($MILLION)
- TABLE 19. MALE HYPOGONADISM MARKET KALLMANN SYNDROME BY COUNTRY, 2020-2030,($MILLION)
- TABLE 20. MALE HYPOGONADISM MARKET REVENUE, FOR PITUITARY DISORDERS, BY REGION , 2020-2030,($MILLION)
- TABLE 21. MALE HYPOGONADISM MARKET PITUITARY DISORDERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 22. MALE HYPOGONADISM MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 23. MALE HYPOGONADISM MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 24. MALE HYPOGONADISM MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 25. NORTH AMERICA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
- TABLE 26. NORTH AMERICA MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 27. NORTH AMERICA MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 28. NORTH AMERICA MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 29. U.S. MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 30. U.S. MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 31. U.S. MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 32. CANADA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 33. CANADA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 34. CANADA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 35. MEXICO MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 36. MEXICO MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 37. MEXICO MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 38. EUROPE MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
- TABLE 39. EUROPE MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 40. EUROPE MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 41. EUROPE MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 42. GERMANY MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 43. GERMANY MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 44. GERMANY MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 45. FRANCE MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 46. FRANCE MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 47. FRANCE MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 48. U.K. MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 49. U.K. MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 50. U.K. MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 51. REST OF EUROPE MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 52. REST OF EUROPE MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 53. REST OF EUROPE MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 54. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
- TABLE 55. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 56. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 57. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 58. JAPAN MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 59. JAPAN MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 60. JAPAN MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 61. CHINA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 62. CHINA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 63. CHINA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 64. INDIA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 65. INDIA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 66. INDIA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 70. LAMEA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
- TABLE 71. LAMEA MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 72. LAMEA MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 73. LAMEA MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 74. LATIN AMERICA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 75. LATIN AMERICA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 76. LATIN AMERICA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 77. MIDDLE EAST MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 78. MIDDLE EAST MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 79. MIDDLE EAST MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 80. AFRICA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
- TABLE 81. AFRICA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 82. AFRICA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 83.ALLERGAN PLC: COMPANY SNAPSHOT
- TABLE 84.ALLERGAN PLC: OPERATING SEGMENTS
- TABLE 85.ALLERGAN PLC: PRODUCT PORTFOLIO
- TABLE 86.ALLERGAN PLC: NET SALES,
- TABLE 87.ALLERGAN PLC: KEY STRATERGIES
- TABLE 88.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 89.PFIZER INC.: OPERATING SEGMENTS
- TABLE 90.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 91.PFIZER INC.: NET SALES,
- TABLE 92.PFIZER INC.: KEY STRATERGIES
- TABLE 93.BAYER AG: COMPANY SNAPSHOT
- TABLE 94.BAYER AG: OPERATING SEGMENTS
- TABLE 95.BAYER AG: PRODUCT PORTFOLIO
- TABLE 96.BAYER AG: NET SALES,
- TABLE 97.BAYER AG: KEY STRATERGIES
- TABLE 98.ELI LILLY AND COMPANY LTD.: COMPANY SNAPSHOT
- TABLE 99.ELI LILLY AND COMPANY LTD.: OPERATING SEGMENTS
- TABLE 100.ELI LILLY AND COMPANY LTD.: PRODUCT PORTFOLIO
- TABLE 101.ELI LILLY AND COMPANY LTD.: NET SALES,
- TABLE 102.ELI LILLY AND COMPANY LTD.: KEY STRATERGIES
- TABLE 103.ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
- TABLE 104.ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
- TABLE 105.ENDO INTERNATIONAL PLC.: PRODUCT PORTFOLIO
- TABLE 106.ENDO INTERNATIONAL PLC.: NET SALES,
- TABLE 107.ENDO INTERNATIONAL PLC.: KEY STRATERGIES
- TABLE 108.MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 109.MERCK & CO., INC.: OPERATING SEGMENTS
- TABLE 110.MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 111.MERCK & CO., INC.: NET SALES,
- TABLE 112.MERCK & CO., INC.: KEY STRATERGIES
- TABLE 113.FERRING: COMPANY SNAPSHOT
- TABLE 114.FERRING: OPERATING SEGMENTS
- TABLE 115.FERRING: PRODUCT PORTFOLIO
- TABLE 116.FERRING: NET SALES,
- TABLE 117.FERRING: KEY STRATERGIES
- TABLE 118.FINOX BIOTEC: COMPANY SNAPSHOT
- TABLE 119.FINOX BIOTEC: OPERATING SEGMENTS
- TABLE 120.FINOX BIOTEC: PRODUCT PORTFOLIO
- TABLE 121.FINOX BIOTEC: NET SALES,
- TABLE 122.FINOX BIOTEC: KEY STRATERGIES
- TABLE 123.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 124.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 125.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 126.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
- TABLE 127.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
- TABLE 128.PERRIGO COMPANY PLC: COMPANY SNAPSHOT
- TABLE 129.PERRIGO COMPANY PLC: OPERATING SEGMENTS
- TABLE 130.PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
- TABLE 131.PERRIGO COMPANY PLC: NET SALES,
- TABLE 132.PERRIGO COMPANY PLC: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.MALE HYPOGONADISM MARKET SEGMENTATION
- FIGURE 2.MALE HYPOGONADISM MARKET,2020-2030
- FIGURE 3.MALE HYPOGONADISM MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.MALE HYPOGONADISM MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.MALE HYPOGONADISM MARKET,BY DRUG DELIVERY,2020(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TOPICAL GELS MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF INJECTABLES MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TRANSDERMAL PATCHES MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 17.MALE HYPOGONADISM MARKET,BY THERAPY,2020(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TESTOSTERONE REPLACEMENT THERAPY MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GONADOTROPIN AND GONADOTROPIN RELEASING HORMONE THERAPY MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 20.MALE HYPOGONADISM MARKET,BY TYPE,2020(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF KLINEFELTERS SYNDROME MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF KALLMANN SYNDROME MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF PITUITARY DISORDERS MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF OTHERS MALE HYPOGONADISM MARKET,2020-2030(%)
- FIGURE 25.MALE HYPOGONADISM MARKET BY REGION,2020
- FIGURE 26.U.S. MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 27.CANADA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 28.MEXICO MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 29.GERMANY MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 30.FRANCE MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 31.U.K. MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 32.REST OF EUROPE MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 33.JAPAN MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 34.CHINA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 35.INDIA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 36.REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 37.LATIN AMERICA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 38.MIDDLE EAST MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 39.AFRICA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
- FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 44.COMPETITIVE DASHBOARD
- FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 46.ALLERGAN PLC.: NET SALES ,($MILLION)
- FIGURE 47.PFIZER INC..: NET SALES ,($MILLION)
- FIGURE 48.BAYER AG.: NET SALES ,($MILLION)
- FIGURE 49.ELI LILLY AND COMPANY LTD..: NET SALES ,($MILLION)
- FIGURE 50.ENDO INTERNATIONAL PLC..: NET SALES ,($MILLION)
- FIGURE 51.MERCK & CO., INC..: NET SALES ,($MILLION)
- FIGURE 52.FERRING.: NET SALES ,($MILLION)
- FIGURE 53.FINOX BIOTEC.: NET SALES ,($MILLION)
- FIGURE 54.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
- FIGURE 55.PERRIGO COMPANY PLC.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook